* Bioventus Inc reported quarterly adjusted earnings of 6 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 5 cents. The mean expectation of three analysts for the quarter was for earnings of 3 cents per share. Wall Street expected results to range from 1 cents to 6 cents per share.
* Revenue rose 15% to $138.96 million from a year ago; analysts expected $133.23 million.
* Bioventus Inc's reported EPS for the quarter was a loss of 7 cents.
* The company reported a quarterly loss of $4.82 million.
* Bioventus Inc shares had fallen by 3.9% this quarter and gained 117.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 18.2% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "hold"
Wall Street's median 12-month price target for Bioventus Inc is 15.00 This summary was machine generated from LSEG data November 6 at 05:04 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.03 0.06 Beat
Jun. 30 2024 0.07 0.19 Beat
Mar. 31 2024 -0.07 0.07 Beat
Dec. 31 2023 0.02 0.07 Beat
Comments